drugset / Trial / NCT01820481

Safety and Efficacy of WIN-901X in Asthma

NCT01820481 ↗

Phase 2 Completed 209 enrolled Whanin Pharmaceutical Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This clinical trial is designed to evaluate the efficacy, dose-response and safety of WIN-901X in Asthma patients.

Timeline

Start
2012-09
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject WIN-901X Unknown 100 mg Oral
Subject WIN-901X Unknown 200 mg Oral
Subject WIN-901X Unknown 300 mg Oral

Indications